Unicycive Therapeutics Inc (UNCY) Stock Price, Quote & News

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 351 4495

Website: unicycive.com

Address:

1975 West El Camino Real, Suite 204, Mountain View, United States

Logmart939 Sep. 16 at 12:20 AM

$UNCY after researching all day I’m 85% sure SHIVA is SHIPLAS subcontractor in question that is awaiting inspection and holding everything up. Please do your own research and help me prove this point and find what was listed in the form 483.

2 · Reply

jimmy18000 Sep. 15 at 11:33 PM

$UNCY latest update says cash runway is into 2027. Wonder if they need cash soon as it’s cutting it close with still no clarity on inspection and the eventual BLA submission.

0 · Reply

Redposition Sep. 15 at 9:29 PM

$UNCY Something fishy 🤔

1 · Reply

chole1 Sep. 15 at 8:07 PM

$UNCY nice trading volume through Citadel... lets assume only good actors in play...

0 · Reply

taki Sep. 15 at 6:42 PM

$UNCY Did not age very well. Again.

1 · Reply

chole1 Sep. 15 at 6:06 PM

$UNCY only logic not to use the other seemingly ready and approved supplier seems to be that this could trigger a different review, potentially longer review cycle, or even a new review? now 2.5 months into the CRL and no news re FDA inspection, that math will not hold for long... hope, or even worse fear that Shilpa's influence on this will not help, this needs to be resolved as quickly as possible (too bad Shilpa is running to the sky on the Indian stock market and we are left in the weeds)

0 · Reply

Aawilliam2003 Sep. 15 at 5:47 PM

$UNCY Gupta is like a frozen deer in the highlights. What does this guy do all day?

2 · Reply

erictwin1 Sep. 15 at 5:20 PM

$UNCY guess ill buy more to bring my 6.05 down some.. Cant believe its dropping this low

2 · Reply

900fix Sep. 15 at 4:17 PM

$UNCY Gupta probably not telling the whole story here. What is he hiding? Inspection should have already been completed. Something being left out. Would a major pharma go through is? Not a chance. This is going way into 2027.

3 · Reply

Eire32 Sep. 15 at 3:40 PM

$UNCY really not much additional information during the webcast, but I felt this time he was very forthcoming and seems very optimistic. I was pleasantly surprised when he mentioned they expect a class one resubmission.

1 · Reply

Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies

Sep 15, 2026, 11:00 AM EDT - 20 hours ago

Unicycive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 9, 2026, 7:00 AM EDT - 7 days ago

Unicycive Therapeutics Slides: Corporate presentation

Sep 1, 2026, 7:05 AM EDT - 15 days ago

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

2026-08-20T12:40:49.000Z - 26 days ago

Unicycive Therapeutics price target raised to $15 from $13 at Benchmark

2026-08-17T09:49:42.000Z - 4 weeks ago

Unicycive Therapeutics reports Q2 EPS (6c), consensus (33c)

2026-08-17T09:06:14.000Z - 4 weeks ago

Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

2026-08-17T08:13:24.000Z - 4 weeks ago

Unicycive Therapeutics price target lowered to $25 from $37 at Guggenheim

Aug 12, 2026, 7:19 AM EDT - 5 weeks ago

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

Unicycive Therapeutics Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

Unicycive Therapeutics Earnings release: Q2 2026

Jul 31, 2026, 7:00 AM EDT - 6 weeks ago

Unicycive Therapeutics Slides: Corporate presentation

2026-07-01T13:45:11.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

2026-07-01T12:50:20.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

Jun 30, 2026, 12:51 PM EDT - 2 months ago

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

2026-06-30T16:35:10.000Z - 2 months ago

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

2026-06-30T14:50:20.000Z - 2 months ago

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

2026-06-30T11:25:41.000Z - 2 months ago

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Jun 30, 2026, 7:05 AM EDT - 2 months ago

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Unicycive Therapeutics Proxy statement: Proxy filing

2026-06-05T20:20:10.000Z - 3 months ago

Unicycive Therapeutics files $150M mixed securities shelf

Jun 5, 2026, 8:00 AM EDT - 3 months ago

Unicycive Therapeutics Registration statement: Registration filing

Jun 4, 2026, 7:00 AM EDT - 3 months ago

Unicycive Therapeutics Slides: Corporate presentation

2026-06-02T13:07:41.000Z - 3 months ago

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Jun 1, 2026, 10:27 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 3 months ago

Unicycive Therapeutics Earnings release

2026-05-28T15:05:39.000Z - 3 months ago

Unicycive Therapeutics management to meet virtually with Piper Sandler

2026-05-13T11:14:54.000Z - 4 months ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

May 13, 2026, 7:00 AM EDT - 4 months ago

Unicycive Therapeutics Slides: Company presentation

2026-05-12T11:51:45.000Z - 4 months ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

May 12, 2026, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

2026-05-01T14:07:09.000Z - 4 months ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Apr 15, 2026, 3:45 PM EDT - 5 months ago

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 5 months ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-04-06T11:30:08.000Z - 5 months ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-02T10:59:29.000Z - 5 months ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Mar 30, 2026, 7:05 AM EDT - 5 months ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 9:15 AM EST - 7 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 4, 2026, 7:05 AM EST - 7 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Jan 29, 2026, 9:15 AM EST - 7 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 7 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Dec 29, 2025, 7:05 AM EST - 8 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 1, 2025, 1:41 PM EST - 9 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Nov 25, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 12, 2025, 7:05 AM EST - 10 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:05 AM EST - 10 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 30, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 28, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Logmart939 Sep. 16 at 12:20 AM

2 · Reply

jimmy18000 Sep. 15 at 11:33 PM

$UNCY latest update says cash runway is into 2027. Wonder if they need cash soon as it’s cutting it close with still no clarity on inspection and the eventual BLA submission.

0 · Reply

Redposition Sep. 15 at 9:29 PM

$UNCY Something fishy 🤔

1 · Reply

chole1 Sep. 15 at 8:07 PM

$UNCY nice trading volume through Citadel... lets assume only good actors in play...

0 · Reply

taki Sep. 15 at 6:42 PM

$UNCY Did not age very well. Again.

1 · Reply

chole1 Sep. 15 at 6:06 PM

0 · Reply

Aawilliam2003 Sep. 15 at 5:47 PM

$UNCY Gupta is like a frozen deer in the highlights. What does this guy do all day?

2 · Reply

erictwin1 Sep. 15 at 5:20 PM

$UNCY guess ill buy more to bring my 6.05 down some.. Cant believe its dropping this low

2 · Reply

900fix Sep. 15 at 4:17 PM

3 · Reply

Eire32 Sep. 15 at 3:40 PM

1 · Reply

Legendary_Scoober Sep. 15 at 3:24 PM

$UNCY in summary: inspection is scheduled, no one knows when, after that it’s 60 day type 1 resubmit. For what it’s worth, they are saying they have been in constant contact with fda.

0 · Reply

Johnnytwofour Sep. 15 at 3:22 PM

$UNCY Good call, still just waiting on the FDA to get their act together. All other pieces in place and enough capital to execute. Steady as she goes boys.

0 · Reply

Legendary_Scoober Sep. 15 at 3:19 PM

$UNCY they have a backup vendor, in case the inspection fails. He says they were surprised by the fda not inspecting before the crl. He also says he knows that the investors are upset. There is only one roadblock, the inspection, duh. All because of a package label issue.

0 · Reply

Aawilliam2003 Sep. 15 at 3:14 PM

$UNCY inspection still has not happened. This makes no sense at all

0 · Reply

Legendary_Scoober Sep. 15 at 3:10 PM

$UNCY fda is saying it will be a surprise inspection, and Gupta has no idea when it will happen. He is saying type 1 resubmission.

0 · Reply

chole1 Sep. 15 at 2:46 PM

$UNCY with all the time passed since the first CRL, UNCY would have been better off with another partner than Shilpa/CMO and cld re-file with another party? Exclusivity seems to hinder progress...

0 · Reply

Logmart939 Sep. 15 at 2:11 PM

$UNCY everyone just relax the volume isn’t pointing to leaked bad news. It’s moving with the markets, EVERYONE is loosing money today.

3 · Reply

Legendary_Scoober Sep. 15 at 1:59 PM

$UNCY I’ll be listening to the conference. I’ll take notes if anything is said.

1 · Reply

erictwin1 Sep. 15 at 1:39 PM

$UNCY sinking fast, heres comes the bad news

1 · Reply

Logmart939 Sep. 15 at 12:55 PM

$UNCY FDA recently conducting a cluster of inspections in the broader region around SHIPLA?? Is Shipla next? Have they already been inspected? GOTTA BE GOOD NEWS COMING GENTS!

1 · Reply

TakeAHike Sep. 14 at 6:14 PM

$UNCY This was Aug 12. Inspection should happen soon if not already, just waiting on results and then boom! If passes.

3 · Reply

11thestate Sep. 14 at 1:05 PM

In the end, $UNCY investors were left with the stock down more than 39% and stuck with their losses. Here’s an update worth your attention: a new case was recently filed against Unicycive Therapeutics over claims that the company misled investors about progress by its third-party manufacturing vendor in resolving FDA-cited deficiencies for its lead drug candidate. After the FDA issued a second Complete Response Letter citing the same manufacturing deficiencies, $UNCY fell 39.1% Check out the latest case updates and learn how to join the case here: https://11th.com/cases/unicycivetherapeutics-investor-suit

2 · Reply

Market Cap	143.45M
Revenue (ttm)	0.00
Net Income (ttm)	-26.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,690,900
Avg Vol	866,296
Day's Range	N/A - N/A
Shares Out	27.86M
Stochastic %K	0%
Beta	1.79
Analysts	Strong Sell
Price Target	$28.22